Double-in vitro maturation increases the number of vitrified oocytes available for fertility preservation when ovarian stimulation is unfeasible.
Adult
Breast Neoplasms
/ physiopathology
Cryopreservation
/ methods
Female
Fertility Preservation
/ methods
Humans
In Vitro Oocyte Maturation Techniques
/ methods
Infertility, Female
/ physiopathology
Oocyte Retrieval
/ methods
Oocytes
/ physiology
Ovulation Induction
/ methods
Retrospective Studies
Vitrification
Young Adult
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
29 10 2020
29 10 2020
Historique:
received:
08
06
2020
accepted:
19
10
2020
entrez:
30
10
2020
pubmed:
31
10
2020
medline:
5
3
2021
Statut:
epublish
Résumé
When ovarian stimulation is unfeasible, in vitro maturation (IVM) represents an alternative option for fertility preservation (FP). This retrospective study aims to evaluate the feasibility of performing within a short time frame two IVM cycles for FP. Seventeen women with breast cancer, 18-40 years of age, having undergone 2 cycles of IVM followed by oocyte vitrification were included. Non parametric analyses were used. No difference was observed between IVM1 and IVM2 outcomes. No complication was reported. The respective contributions of IVM1 and IVM2 for the number of cryopreserved oocytes were comparable irrespective of the delay between both procedures, even when performed during the same menstrual cycle. Those findings suggest that repeating IVM cycles may constitute a safe option for increasing the number of vitrified mature oocytes for FP. These two retrievals may be performed during the same cycle, providing additional argument for a physiologic continuous recruitment during follicular development.
Identifiants
pubmed: 33122722
doi: 10.1038/s41598-020-75699-x
pii: 10.1038/s41598-020-75699-x
pmc: PMC7596087
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
18555Références
Fertil Steril. 2019 Feb;111(2):357-362
pubmed: 30527837
Future Oncol. 2012 Dec;8(12):1567-73
pubmed: 23231518
J Assist Reprod Genet. 2020 Jan;37(1):149-158
pubmed: 31701304
Fertil Steril. 2016 Mar;105(3):755-764.e8
pubmed: 26688429
Hum Reprod Update. 2012 Jan-Feb;18(1):73-91
pubmed: 22068695
J Clin Oncol. 2013 Jul 1;31(19):2500-10
pubmed: 23715580
Fertil Steril. 2008 Mar;89(3):567-72
pubmed: 17543957
Reprod Biomed Online. 2014 Dec;29(6):684-91
pubmed: 25444501
Reprod Biomed Online. 2008 Oct;17(4):520-3
pubmed: 18854106
Hum Reprod. 2019 Sep 29;34(9):1778-1787
pubmed: 31398253
Hum Reprod. 2015 Jan;30(1):81-7
pubmed: 25362088
Fertil Steril. 2009 Oct;92(4):1360-1365
pubmed: 18930226
Fertil Steril. 2013 Nov;100(5):1214-23
pubmed: 24011612
Ann Oncol. 2020 Apr;31(4):541-542
pubmed: 32085890
Fertil Steril. 2013 Dec;100(6):1681-5.e1
pubmed: 24055050
J Assist Reprod Genet. 2010 Aug;27(8):491-4
pubmed: 20455017
Hum Reprod. 2018 Aug 1;33(8):1442-1448
pubmed: 29912374
Hum Fertil (Camb). 2017 Dec;20(4):248-253
pubmed: 28423955
Hum Reprod. 2018 Dec 1;33(12):2222-2231
pubmed: 30383235
Reprod Biomed Online. 2002 Sep-Oct;5(2):125-32
pubmed: 12419036
Fertil Steril. 2015 May;103(5):1194-1201.e2
pubmed: 25813280
Hum Reprod. 2016 Jul;31(7):1493-500
pubmed: 27165625
Front Endocrinol (Lausanne). 2018 Jun 14;9:317
pubmed: 29963011
Biol Reprod. 2003 Sep;69(3):1023-31
pubmed: 12748128
Fertil Steril. 2015 Dec;104(6):1426-34.e1-8
pubmed: 26353081
Fertil Steril. 2013 Dec;100(6):1673-80
pubmed: 23987516
J Assist Reprod Genet. 2012 Jun;29(6):465-8
pubmed: 22648282
Fertil Steril. 2016 Jun;105(6):1488-1495.e1
pubmed: 27020168
Hum Reprod. 2016 Mar;31(3):623-9
pubmed: 26759139